HALKUFF DAWN 4

What Happened

• Dawn Halkuff, a director of Xeris Biopharma (XERS), sold 20,000 shares in an open-market transaction on June 4, 2026 for a weighted average price of $6.09, generating $121,886 in proceeds.
• On the same date she was granted 24,193 restricted stock units (RSUs) (no purchase price) and a derivative grant of 32,996 stock options/awards with a reported price basis of $6.15 (total reported value for the derivative grant ~$202,925). The RSUs and options vest in full upon the earlier of June 4, 2026 or the company’s next annual meeting, subject to continued service.

Key Details

• Transaction date: June 4, 2026; Form 4 filed June 5, 2026 (timely).
• Sale details: 20,000 shares sold, weighted-average price $6.09; sale prices ranged $5.96–$6.17 (report notes multiple trades).
• Grants: 24,193 RSUs (F3) and 32,996 stock option-type awards (F5) were reported as acquired. Vesting is contingent on continued service and the earlier of June 4, 2026 or the next annual meeting.
• Footnotes: Sale executed under a pre-established Rule 10b5-1 trading plan adopted Sept 4, 2025 (F1). Reporting person disclaims beneficial ownership except for pecuniary interest (F4).
• Shares owned after the transactions are not specified in the filing.

Context

• The sale was effected under a 10b5-1 plan (pre-set trading arrangement), which is typically used to sell shares systematically rather than as an ad-hoc indicator of sentiment.
• The reported awards are grants (not exercises) and will vest subject to service conditions; they are not immediate cash or share sales.